Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
Liu, J.S., Fang, W.K., Yang, S.M., Wu, M.C., Chen, T.J., Chen, C.M., Lin, T.Y., Liu, K.L., Wu, C.M., Chen, Y.C., Chuu, C.P., Wang, L.Y., Hsieh, H.P., Kung, H.J., Wang, W.C.(2022) J Biomed Sci 29: 29-29
- PubMed: 35534851 
- DOI: https://doi.org/10.1186/s12929-022-00812-3
- Primary Citation of Related Structures:  
7EQV - PubMed Abstract: 
Castration-resistant prostate cancer (CRPC) with sustained androgen receptor (AR) signaling remains a critical clinical challenge, despite androgen depletion therapy. The Jumonji C-containing histone lysine demethylase family 4 (KDM4) members, KDM4A‒KDM4C, serve as critical coactivators of AR to promote tumor growth in prostate cancer and are candidate therapeutic targets to overcome AR mutations/alterations-mediated resistance in CRPC.
Organizational Affiliation: 
Institute of Molecular and Cellular Biology and Department of Life Sciences, National Tsing-Hua University, Hsinchu, 30013, Taiwan.